Furthermore, both PX-478 and EZN2968 elicit dose-dependent decreases in HIF-1α levels and VEGF expression, as well as the tumor size in DU145 xenograft models, and both small-molecule inhibitors were well tolerated in clinical activities [241,242]. The gene discussed is HIF1A; the disease is neoplasm.